gadopenteate dimeglumine (magnevist) Report issue

Small molecule Imaging Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Gadopentetic acid, sold under the brand name Magnevist, is a gadolinium-based MRI contrast agent.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

diethylenetriaminepentaacetic acid dimeglumine salt gadolinium chelate | dimeglumine-gadolinium-dtpa | gadopentate dimeglumine | gadopentetate dimeglumine | gadopentetic acid | gadopentetic acid dimeglumine salt | gd-dtpa | magnevist | meglumine gadopentetate | sh l 451 a | sh-l 451 a

Organizations (27)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

Diagnostic Imaging (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Aortic Diseases (Phase 3)

Astrocytoma (Early Phase 1)

Brain Neoplasms (Phase 4)

Breast Neoplasms (Phase 4)

Cardiovascular Abnormalities (Phase 3)

Central Nervous System Diseases (Phase 3)

Constriction, Pathologic (Phase 3)

Diagnostic Self Evaluation (Phase 3)

Ependymoma (Early Phase 1)

Fibrosis (Phase 4)

Glioblastoma (Early Phase 1)

Gliosarcoma (Early Phase 1)

Healthy Volunteers (Phase 1)

Heart Defects, Congenital (Phase 1)

Hypertension, Pulmonary (Phase 1)

Liver Neoplasms (Phase 2)

Magnetic Resonance Angiography (Phase 2)

Magnetic Resonance Imaging (Phase 4)

Myocardial Infarction (Phase 2)

Neoplasms (Phase 2)

Oligodendroglioma (Early Phase 1)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 3)

Positron-Emission Tomography (Phase 4)

Renal Artery Obstruction (Phase 3)

Renal Insufficiency (Phase 4)

Shoulder Injuries (Phase 4)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue